循環器内科専門医バイブル　2　虚血性心疾患　識る・診る・治す・防ぐ

出版社： 中山書店
著者：
発行日： 2018-08-05
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784521745848
電子書籍版： 2018-08-05 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

13,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

13,200 円(税込)

購入する

商品紹介

循環器専門医と専門医を目指す医師のための新シリーズ第2弾．PCIの適応の拡大，デバイスの発展と手技の向上によって，虚血性心疾患の治療は成熟期を迎えている．本書では，動脈硬化の危険因子，疫学，診断・検査，病態に応じた治療，特殊な症例の管理，二次予防，そして診断と治療の最新動向を詳しく解説．常に座右に置いて指針を仰ぐにふさわしい，「バイブル」の名に値する実践書．

目次

  • 序章　虚血性心疾患オーバービュー
    　虚血性心疾患治療の変遷
    　冠動脈インターベンション領域の拡大

    第1章　虚血を識る―虚血性心疾患の疫学と病態
    　動脈硬化症の進展と危険因子
    　冠攣縮の疫学
    　虚血性心疾患の疫学－日本と海外動向との比較
    　院外心停止
    　日本のビックレジストリーからの予後
    　　a．大阪急性冠症候群研究会（OACIS）
    　　b．東京都CCUネットワーク
    　　再狭窄，ステント血栓症の病理

    第2章　虚血を診る－虚血性心疾患の診断
    　冠循環と心筋虚血
    　再灌流障害
    　心電図による検査
    　心臓超音波検査
    　冠動脈CT/MRI
    　心臓核医学による評価とリスク評価
    　冠動脈造影による評価
    　機能的冠動脈狭窄評価
    　IVUS/OCTによる病変評価
    　生化的指標
    　冠攣縮

    第3章　虚血を治す－薬物治療と非薬物治療
    　プレホスピタルケア
    　ACSのトリアージと初期治療
    　STEMIに対する再灌流療法
    　　a．再灌流療法 up date
    　　b．door-to-balloon timeとtotal ischemic time
    　　c．非責任病変に対する治療戦略
    　NSTEMIに対するリスク評価と治療戦略
    　ACS急性期の薬物療法と投薬のタイミング
    　安定狭心症
    　　a. 薬物療法
    　　b．重症度評価と血行再建術
    　　c．CABG手術リスク評価
    　冠攣縮性狭心症
    　無症候性心筋虚血
    　虚血性心筋症と虚血性（収縮性）心不全
    　PCI治療の変遷
    　外科治療の動向

    第4章　Expert Advice－特殊な症例を管理する
    　補助循環のエビデンス
    　糖尿病合併例
    　CKD合併例
    　高齢者の虚血性心疾患
    　虚血性心疾患における性差を考える
    　心房細動合併例
    　虚血性僧帽弁閉鎖不全症
    　TAVIに伴う冠動脈病変
    　冠動脈疾患・心不全合併例における血行再建
    　虚血性心疾患の非心臓手術
    　川崎病冠動脈後遺症を有する患者をいかに治療・管理するか

    第5章　虚血を防ぐ－虚血性心疾患の二次予防
    　OMTの概念－虚血性心疾患の二次予防としてのOMT
    　抗血栓薬
    　高血圧の治療
    　脂質異常の治療薬
    　糖尿病治療薬
    　左室Rリモデリング予防
    　生活スタイルの改善と心臓リハビリテーション

    第6章　Current Topics－診断と治療の最新動向
    　BRS（生体吸収性スキャフォールド）の動向
    　FFR CT/QFR
    　AUCの概念と日米間の差異
    　ハートチーム
    　脂質管理の限界
    　DES後のOptimal DAPT期間
    　移植心の冠動脈疾患
    　ロボティック　PCI
    　ステント再狭窄に対する治療
    　プラークイメージング

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章 虚血性心疾患オーバービュー

P.7 掲載の参考文献
1) Kannel WB, et al. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med 1961 ; 55 : 33-50.
PubMed
2) Mueller RL, Sanborn TA. The history of interventional cardiology : Cardiac catheterization, angioplasty, and related interventions. Am Heart J 1995 ; 129 : 146-72.
PubMed
3) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction : ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988 ; 2 : 349-60.
 
4) Cholesterol Treatment Trialists' Collaboration, et al. Efficacy and safety of more intensive lowering of LDL cholesterol : A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 : 376 : 1670-81.
 
5) Boden WE, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007 ; 356 : 1503-16.
 
6) Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med 2012 ; 366 : 54-63.
PubMed
P.12 掲載の参考文献
1) Schomig A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996 ; 334 : 1084-9.
PubMed
2) Morice MC, et al, RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002 ; 346 : 1773-80.
 
3) Saito S, et al. Primary stent implantation without coumadin in acute myocardial infarction. J Am Coll Cardiol 1996 : 28 : 74-81.
PubMed
4) Teirstein PS, et al. High speed rotational atherctomy for patients with diffuse coronary artery disease. J Am Coll Cardiol 1991 ; 18 : 1694-701.
 
5) Boden WE et al : COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007 ; 356 : 1503-16.
PubMed

第1章 虚血を識る - 虚血性心疾患の疫学と病態

P.19 掲載の参考文献
1) Libby P, et al. Progress and challenges in translating the biology of atherosclerosis. Nature 2011 ; 473 : 317-25.
PubMed
2) Bentzon JF et al. Mechanisms of plaque formation and rupture. Circ Res 2014 ; 114 : 1852-66.
PubMed
3) King GL, et al. Selective Insulin Resistance and the Development of Cardiovascular Diseases in Diabetes : The 2015 Edwin Bierman Award Lecture. Diabetes 2016 ; 65 : 1462-71.
PubMed
4) Cusi K, et al. Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000 : 105 : 311-20.
PubMed
P.25 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2012年度合同研究報告) : 冠攣縮性狭心症の診断と治療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawah_h.pdf
 
2) Takagi Y, et al. Clinical characteristics and long-term prognosis of vasospastic angina patients who survived out-of-hospital cardiac arrest : Multicenter registry study of the Japanese Coronary Spasm Association. Circ Arrhythm Electrophysiol 2011 ; 4 : 295-302.
PubMed
3) Sato K, et al. Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm : Analysis of a single-center study over 20 years. J Am Heart Assoc 2013 ; 2 : e000227.
PubMed
4) Pristipino C, et al, Major racial differences in coronary constrictor response between Japanese and caucasians with recent myocardial infarction. Circulation 2000 ; 101 : 1102-8.
PubMed
5) Nakayama N, et al, Clinical features and prognosis of patients with coronary spasm-induced non-ST-segment elevation acute coronary syndrome. J Am Heart Assoc 2014 ; 3 : e00079S.
PubMed
6) Ong P, et al. Coronary artery spasm as a frequent cause of acute coronary syndrome : The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol 2008 ; 52 : 523-7.
PubMed
P.31 掲載の参考文献
1) 厚生労働省. 平成27年 (2015) 人口動態統計 (確定数) の概況. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei15/d1/00_all.pdf (最終アクセス日 : 2017年10月30日)
 
2) Tanaka H, et al. Research activities of epidemiology in Japan, cardiovascular disease : A brief review of epidemiologicai studies on ischemic heart disease in Japan. J Epidemiol 1996 ; 6 : S49-59.
PubMed
3) 北村明彦ほか. 地域住民男子における循環器疾患発症の動向とその背景要因-都市部と農村部における長期の疫学調査成績より. 日本公衆衛生雑誌 2001 ; 48 : 378-94.
 
4) Hao K, et al. Urbanization, life style changes and the incidence/in-hospital mortality of acute myocardial infarction in Japan : Report from the MIYAGI-AMI Registry Study. Circ J 2012 ; 76 : 1136-44.
PubMed
5) Kojima S, et al. Temporal trends in hospitalization for acute myocardial infarction between 2004 and 2011 in Kumamoto, Japan. Circ J 2013 ; 77 : 2841-3.
PubMed
6) 厚生労働省健康局総務課. 生活習慣病対策室. 第5次循環器疾患基礎調査結果の概要. http://www.mhlw.go.jp/toukei/saikin/hw/kenkou/jyunkan/jyunkan00/gaiyo.html (最終アクセス日 : 2017年10月30日)
 
7) 厚生労働省循環器病委託研究費. 虚血性心疾患における冠攣縮の役割に関する研究 (10公-5). 平成12年度厚生省循環器病研究委託費による研究報告書. 2001.
 
8) Yeh RW, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010 ; 362 : 2155-65.
PubMed
9) National Institutes of Health NH, Lung, and Blood Institute. Morbidity & Mortality : 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases, Bethesda, MD : National Heart, Lung, and Blood Institute ; 2012.
 
10) Ong P. et al. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol. 2012 ; 59 : 655-62.
PubMed
11) 政府統計の総合窓口 (e-Stat). http://www.e-stat.go.jp/SG1/estat/Listdo?lid=000001191145
 
12) WHO Mortality database. http://apps.who.int/healthinfo/statistics/mortality/whodprns/ (最終アクセス日 : 2017年10月30日)
 
13) Takii T, et al. Trends in acute myocardial infarction incidence and mortality over 30 years in Japan : Report from the MIYAGI-AMI Registry Study. Circ J 2010 ; 74 : 93-100.
PubMed
14) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告) : 虚血性心疾患の一次予防ガイドライン (2012年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2012_shimamoto_h.pdf (最終アクセス日 : 2017年10月30日)
 
15) Shiba N, et al. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-First report from the CHART-2 study. Circ J 2011 ; 75 : 823-33.
PubMed
16) Nishimura K, et al. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score : The suita study. J Atheroscler Thromb 2014 ; 21 : 784-98.
PubMed
P.37 掲載の参考文献
1) American Heart Association in collaboration with International Liaison Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care : International consensus on science. Circulation 2000 ; 102 (Supple I) : I-1-384.
 
2) International Liaison Committee on Resuscitation. 2005 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation 2005 ; 112 : III-1-136.
 
3) International Liaison Committee on Resuscitation. 2010 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation 2010 : 122 : s-249-638.
 
4) International Liaison Committee on Resuscitation．2015 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation 2015 ; 132 Suppl 1 : S1-311.
 
5) AHA 2016. Best abstract awardを授与されたJCS-ReSS Group研究
 
6) SOS-KANTO study group. Cardiopulmonary resuscitation by bystanders with chest compression only (SOS-KANTO) : An observational study. Lancet 2007 ; 369 : 920-6.
 
7) Nagao K. Chest compression-only cardiocerebral resuscitation. Curr Opin Crit Care 2009 ; 15 : 189-97.
PubMed
8) 長尾建ほか. 虚血性突然心停止. 日本内科学雑誌 2004 ; 93 : 300-5.
 
9) Nagao K, et al. Japanese Circulation Society With Resuscitation Science Study (JCS-ReSS) Group. Duration of prehospital resuscitation efforts after out-of-hospital cardiac arrest. Circulation 2016 ; 133 : 1386-96.
PubMed
10) Sakamoto T, et al. SAVE-J Study Group. Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with out-of-hospital cardiac arrest : A prospective observational study. Resuscitation 2014 ; 85 : 762-8.
 
11) Kitamura T, et al. Public-access defibrillation and out-of-hospital cardiac arrest in Japan. N Engl J Med 2016 ; 375 : 1649-59.
PubMed
12) Kitamura T, et al. Nationwide public-access defibrillation in Japan. N Engl J Med 2010 ; 362 : 994-1004.
PubMed
P.47 掲載の参考文献
1) Edahiro R, et al. Association of lifestyle-related factors with circadian onset patterns of acute myocardial infarction : a prospective observational study in Japan. BMJ Open 2014 ; 4 : e005067.
PubMed
2) Nakatani D, et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol 2013 ; 111 : 457-64.
 
3) Nakatani D, et al. Effect of intracoronary thrombectomy on 30-day mortality in patients with acute myocardial infarction. Am J Cardiol 2007 ; 100 : 1212-7.
PubMed
4) Masuda M, et al. Clinical Impact of Ventricular Tachycardia and/or Fibrillation During the Acute Phase of Acute Myocardial Infarction on In-Hospital and 5-Year Mortality Rates in the Percutaneous Coronary Intervention Era. Circ J 2016 ; 80 : 1539-47.
PubMed
5) Nakatani D, et al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J 2013 ; 77 : 439-46.
PubMed
6) Ozaki K, et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature 2004 ; 429 : 72-5.
PubMed
7) Suna S, et al. Decreased mortality associated with statin treatment in patients with acute myocardial infarction and lymphotoxin-alpha C804A polymorphism. Atherosclerosis 2013 ; 227 : 373-9.
PubMed
P.53 掲載の参考文献
1) 山本剛, 高山守正. 東京都CCUネットワーク. 冠疾患誌 2015 ; 21 : 132-6.
 
2) 山本剛, 高山守正. 心原性ショックの疫学-レジストリーデータから. ICUとCCU 2017 ; 41 : 531-7.
Medical*Online
3) Miyachi H, et al. Current characteristics and management of ST elevation and non-ST elevation myocardial infarction in the Tokyo metropolitan area : From the Tokyo CCU network registered cohort. Heart Vessels 2016 ; 31 : 1740-51.
PubMed
4) Yamamoto T, Takayama M. Recent trends in the incidence and short-term outcomes of hospitalized patients with acute myocardial infarction in Tokyo. Circ J (in submission)
 
5) 山本剛ほか. 東京都CCUネットワークの活動状況報告 2015. ICUとCCU 2017 ; 41 : S6-8.
 
6) Reynolds HR, Hochman JS. Cardiogenic shock : Current concepts and improving outcomes. Circulation 2008 ; 117 : 686-97.
PubMed
7) 高山守正, 高野照夫. 東京都CCUネットワークにおける患者集計の解析-急性心筋梗塞における再疎通療法. 循環器専門医 2002 ; 10 : 21-6.
 
8) 高山守正ほか. 緊急心血管治療の概要および急性心筋梗塞の動向. ICUとCCU 2009 ; 33 : 844-9.
Medical*Online
9) Kolte D, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc 2014 ; 3 : e000590.
PubMed
P.61 掲載の参考文献
1) Jawien A, et al. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992 ; 89 : 507-11.
 
2) Mintz GS, et al. Arterial remodeling after coronary angioplasty : a serial intravascular ultrasound study. Circulation 1996 ; 94 : 35-43.
PubMed
3) Serruys PW, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994 ; 331 : 489-95.
 
4) Farb A, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002 ; 105 : 2974-80.
PubMed
5) Gonzalo N, et al. Optical coherence tomography patterns of stent restenosis. Am Heart J 2009 ; 158 : 284-93.
PubMed
6) Nagai H, et al, Histology of highly echolucent regions in optical coherence tomography images from two patients with sirolimus-eluting stent restenosis. Catheter Cardiovasc Interv 2010 ; 75 : 961-3,
PubMed
7) Joner M, et al. Pathology of drug-eluting stents in humans : delayed healing and late thrombotic risk. J Am Coll Cardiol 2006 : 48 : 193-202.
 
8) Nakano M, et al. Human autopsy study of drug-eluting stents restenosis : histomorphological predictors and neointimai characteristics. Eur Heart J 2013 ; 34 : 3304-13.
PubMed
9) McFadden EP, et al. Late thrombosis in drug-eluting coronary stents after disc. ontinuation of antiplatelet therapy. Lancet 2004 ; 364 : 1519-21.
 
10) Nakazawa G, et al. Coronary responses and differential mechanisms of late stent throrllbosis attributed to first-generation sirolimus-and paclitaxel-eluting stents. J Am Coll Cardiol 2011 ; 57 : 390-8.
PubMed
11) Nakazawa G, et al, Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients : an autopsy study. Circulation 2008 ; 118 : 1138-45.
PubMed
12) Nakazawa G, et al. Pathological findings at bifurcation lesions : the impact of flow distribution on atherosclerosis and arterial healing after stent implantation. J Am Coll Cardiol 2010 ; 55 : 1679-87.
PubMed
13) Nakazawa G. Stent thrombosis of drug eluting stent : pathological perspective. J Cardiol 2011 ; 58 : 84-91.
PubMed
14) Virmani R, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent : should we be cautious? Circulation 2004 ; 109 : 701-5.
PubMed
15) Otsuka F, et al. Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents : histopathological assessment with ex vivo optical coherence tomography. Circulation 2015 ; 131 : 322-4.
PubMed
16) Nakazawa G, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011 ; 57 : 1314-22.
PubMed
17) Otsuka F, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus-and paclitaxel-eluting stents in humans. Circulation 2014 ; 129 : 211-23.
PubMed
18) Natsuaki M, et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation : ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther 2016 ; 31 : 196-209.
PubMed

第2章 虚血を診る - 虚血性心疾患の診断

P.69 掲載の参考文献
Leonard SL編 (川名正敏, 川名陽子訳). 虚血性心疾患. 心臓病の病態生理. ハーバード大学テキスト第3版. メディカル・サイエンス・インターナショナル ; 2012 p. 145-72.
 
P.74 掲載の参考文献
1) Frohlich GM, et al. Myocardial reperfusion injury : looking beyond primary PCI. Eur Heart J 2013 ; 34 : 1714-22.
PubMed
2) Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007 ; 357 : 1121-35.
PubMed
3) Bulluck H, et al. Reducing myocardial infarct size : challenges and future opportunities. Heart 2016 ; 102 : 341-8.
PubMed
4) Kitakaze M, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND) : two randomised trials. Lancet 2007 ; 370 : 1483-93.
PubMed
P.81 掲載の参考文献
1) Kosuge M, et al. ST-segment depression in lead aVR predicts predischarge left ventricular dysfunction in patients with reperfused anterior acute myocardial infarction with anterolateral ST-segment elevation. Am Heart J 2001 ; 142 : 51-7.
PubMed
2) 小菅雅美. 木村一雄監. 心電図で見方が変わる急性冠症候群. 文光堂 ; 2015.
 
3) Kosuge M, et al. New electrocardiographic criteria for predicting the site of coronary artery occlusion in inferior wall acute myocardial infarction. Am J Cardiol 1998 ; 82 : 1318-22.
PubMed
P.88 掲載の参考文献
1) Lang RM, et al. Recommendations for cardiac chamber quantification by echocardiography in adults : An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015 ; 28 : 1-39.
PubMed
2) Pellikka PA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007 ; 20 : 1021-41.
PubMed
3) Schinkel AF, et al. Noninvasive evaluation of ischemic heart disease : myocardial perfusion imagingor stress echocardiography? Eur Heart J 2003 ; 24 : 789-800.
PubMed
4) Voigt JU, et al. Strain-rate imaging during dobutamine stress echocardiography provides objective evidence of inducible ischemia, Circulation 2003 ; 107 : 2120-6.
PubMed
5) Ishii K, et al. Exercise-induced post-ischemic left ventricular delayed relaxation or diastolic stunning : is it a reliable marker in detecting coronary artery disease? J Am Coll Cardiol 2009 ; 53 : 698-705.
PubMed
P.92 掲載の参考文献
1) Yamamoto H, et al. Coronary calcium score as a predictor for coronary artery disease and cardiac events in Japanese high-risk patients. Circ J 2011 ; 75 : 2424-31.
PubMed
2) Taylor AJ, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Circulation 2010 ; 122 : e525-55.
 
3) Hamon M. et al. Coronary arteries : diagnostic performance of 16-versus 64-section spiral CT compared with invasive coronary angiography-meta-analysis. Radiology 2007 ; 245 : 720-31.
PubMed
4) Motoyama S, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 2009 ; 54 : 49-57.
PubMed
5) Motoyama S, et al. Plaque Characterization by Coronary Computed Tomography Angiography and the Llikelihood of Acute Coronary Events in Mid-Term Follow-Up. J Am Coll Cardiol 2015 ; 66 : 337-46.
PubMed
6) Ishida S, Sakuma H. Magnetic Resonance Coronary Angiography : Present Clinical Applications and Future Perspectives. J Jpn Coll Angiol 2009 ; 49 : 473-80.
 
P.98 掲載の参考文献
1) Nishimura T, et al. Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT : J-ACCESS study. Eur J Nucl Med Mol Imaging 2008 ; 35 : 319-28.
PubMed
2) Matsumoto N, et al. Prognostic value of myocardial perfusion single-photon emission computed tomography for the prediction of future cardiac events in a Japanese population : a middle-term follow-up study. Circ J 2007 ; 71 : 1580-5.
 
3) Murthy VL, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 2011 ; 124 : 2215-24.
PubMed
4) Montalescot G, et al. 2013 ESC guidelines on the management of stable coronary artery disease : the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013 ; 34 : 2949-3003.
 
5) Hachamovitch R, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003 ; 107 : 2900-7.
PubMed
6) Hachamovitch R, et al, Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011 ; 32 : 1012-24.
PubMed
7) Agostini D, et al. First validation of myocardial flow reserve assessed by dynamic99mTc-sestamibi CZT-SPECT camera : head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study. Eur J Nucl Med Mol Imaging 2018 ; 45 : 1079-90.
PubMed
P.104 掲載の参考文献
1) Sakata K, et al. Diffuse and severe left ventricular dysfunction induced by epicardial coronary artery spasm. Angiology 2000 ; 51 : 837-47.
PubMed
2) Inami T, et al. Left ventricular dysfunction due to diffuse multiple vessel coronary artery spasm can be concealed in dilated cardiomyopathy. Eur J Heart Fail 2012 ; 14 : 1130-8.
PubMed
3) Kaneide H, et al. Transmural anoxic wave front and regional dysfunction during early ischemia. Am J Physiol 1987 ; 253 : H240-7.
 
4) Yoshino H, et al. Asynergy of the noninfarcted left ventricular inferior wail in anterior wall acute myocardial infarction secondary to isolated occlusion of the left anterior descending artery. Am J Cardiol 1998 ; 81 : 828-33.
 
P.110 掲載の参考文献
1) Gould KL, et al. Physiologic basis for assessing critical coronary stenosis : Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 1974 ; 33 : 87-94.
PubMed
2) Miller DD, et al. Correlation of pharmacological 99mTc-sestamibi myocardial perfusion imaging with poststenotic coronary flow reserve in patients with angiographically intermediate coronary artery stenoses. Circulation 1994 : 89 : 2150-60.
PubMed
3) Daimon M, et al. Physiologic assessment of coronary artery stenosis by coronary flow reserve measurements with transthoracic Doppler echocardiography : comparison with exercise thallium-201 single piston emission computed tomography. J Am Coll Cardiol 2001 ; 37 : 1310-5.
PubMed
4) Pijls NH, et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation 1993 ; 87 : 1354-67.
PubMed
5) Pijls NH, et al. Measurement of fractional flow reserve to assess the functional severity of coronary artery stenoses. N Engl J Med 1996 ; 334 : 1703-8.
PubMed
6) Pijls NH, et al, Percutaneous coronary intervention of functionally nonsignificant stenosis : 5 year follow-up of the DEFER Study. J Am Coll Cardiol 2007 ; 49 : 2105-11.
PubMed
7) Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009 ; 360 : 213-24.
PubMed
8) Zimmermann FM, et al. Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis : 15-year follow-up of the DEFER trial. Eur Heart J 2015 : 36 : 3182-8.
PubMed
9) Tanaka N, et al. One-Year Outcome of Fractional Flow Reserve-Based Coronary Intervention in Japanese Daily Practice-CVIT-DEFER Registry. Circ J 2017 ; 81 : 1301-6.
PubMed
10) Tanaka N, et al. Analysis of suboptimal stent deployment using intravascular ultrasound and coronary pressure pullback measurement. J Cardiol 2017 ; 69 : 613-8.
PubMed
11) Davies JE, et al. Evidence of a dominant backward-propagating "suction" wave responsible for diastolic coronary filling in humans, attenuated in left ventricular hypertrophy. Circulation 2006 ; 113 : 1768-78.
PubMed
12) Sen S, et al. Deveiopment and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis : results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. J Am Coll Cardiol 2012 ; 59 : 1392-402.
 
13) Davies JE, et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med 2017 ; 376 : 1824-34.
 
P.116 掲載の参考文献
1) Goldstein JA, et al. Detection of lipid-core plaques by intracoronary near-infrared spectroscopy identifies high risk of periprocedural myocardial infarction. Circ Cardiovasc Interv 2011 ; 4 : 429-37.
PubMed
2) Jia H, et al. Effective anti-thrombotic therapy without stenting : intravascular optical coherence tomography-based management in plaque erosion (the EROSION study). Eur Heart J 2017 ; 38 : 792-800.
PubMed
P.121 掲載の参考文献
1) Ehara S, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001 ; 103 : 1955-60,
PubMed
2) Tajika K, et al. Malondialdehyde-modified low-density lipoprotein is a useful marker to identify patients with vulnerable plaque. Circ J 2012 ; 76 : 2211-7.
PubMed
3) Hayashida K, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome : a novel marker for early diagnosis. Circulation 2005 ; 112 : 812-8.
PubMed
4) Kobayashi A, et al. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a valuable diagnostic marker for rupture of thin-cap fibroatheroma : verification by optical coherence tomography. Int J Cardiol 2013 ; 168 : 3217-23.
 
5) Park JP, et al. Relationship between multiple plasma biomarkers and vulnerable plaque determined by virtual histology intravascular ultrasound. Circ J 2010 ; 74 : 332-6.
PubMed
6) Thygesen K, et al. Universal definition of myocardial infarction. Eur Heart J 2007 ; 28 : 2525-38.
PubMed
7) Newby LK, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations : a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2012 ; 60 : 2427-63.
 
8) Kitamura M, et al. High-sensitivity cardiac troponin T for earlier diagnosis of acute myocardial infarction in patients with initially negative troponin T test-Comparison between cardiac markers. J Cardiol 2013 ; 62 : 336-42.
PubMed
9) Kitamura M, et al. Different characteristics of cardiac biomarkers to decide and predict the culprit lesions in patients with suspicious acute coronary syndrome. Heart Vessels 2016 ; 31 : 907-17.
PubMed
P.128 掲載の参考文献
1) Yasue H, Kugiyama K. Coronary spasm : clinical features and pathogenesis. Intern Med 1997 ; 36 : 760-5.
PubMed
2) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告) : 冠攣縮性狭心症の診断と治療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawah_h.pdf
 

第3章 虚血を治す - 薬物治療と非薬物治療

P.135 掲載の参考文献
1) American Heart Association. American Heart Association心肺蘇生と救急心血管治療のためのガイドラインアップデート2015ハイライト. p.4. https://eccguidelines.heart.org/wp-content/uploads/2015/10/2015-AHA-Guidelines-Highlights-Japanese.pdf
 
2) Canto JG, et al ; National Registry of Myocardial Infarction 2 Investigators. Use of emergency medical services in acute myocardial infarction and subsequent quality of care : observations from the National Registry of Myocardial Infarction 2. Circulation 2002 ; 106 : 3018-23.
 
3) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告) : ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf
 
4) 日本蘇生協議会. 急性管症候群 (ACS), JRC蘇生ガイドライン2015オンライン版. http://www.japanresuscitationcouncil.org/wp-content/uploads/2016/04/4f63e3aa0fcd083d92435f391d343f16.pdf.
 
5) 田原良雄, 木村一雄, 急性冠症候群に対するプレホスピタル12誘導心電図を含む循環器救急診療システムの重要性. 冠疾患誌 2012 ; 18 : 84-8.
 
6) Siriwardena AN, et al. The effect of a national quality improvement collaborative on prehospital care for acute myocardial infarction and stroke in England. Implement Sci 2014 ; 9 : 17.
PubMed
7) Ouellet GM, et al. Prehospital Delay in Older Adults with Acute Myocardial Infarction : The ComprehenSIVe Evaluation of Risk Factors in Older Patients with Acute Myocardial Infarction Study. J Am Geriatr Soc 2017 ; 65 : 2391-6.
PubMed
8) Le May MR, et al. Comparison of early mortality of paramedic-diagnosed ST-segment elevation myocardial infarction with immediate transport to a designated primary percutaneous coronary intervention center to that of similar patients transported to the nearest hospital. Am J Cardiol 2006 ; 98 : 1329-33.
 
9) Le May MR, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2008 ; 358 : 231-40.
 
10) Brown JP, et al. Effect of prehospital 12-lead dlectrocardiogram on activation of the cardiac catheterization laboratory and door-to-balloon time in ST-segment elevation acute myocardial infarction. Am J Cardiol 2008 ; 101 : 158-61.
 
11) Hofmann R, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. N Engl J Med 2017 ; 377 : 1240-9.
PubMed
P.141 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告) : ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf
 
2) Roffi M, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016 ; 37 : 267-315.
 
P.147 掲載の参考文献
1) Ibanez B, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018 ; 39 : 119-77.
 
2) Valgimigli M, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management : a randomised multicentre trial. Lancet 2015 ; 385 : 2465-76.
PubMed
3) Jolly SS, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 2015 ; 372 : 1389-98.
 
4) Sabate M, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-etuting stents versus bare-metal stents (EXAMINATION) : 5-year results of a randomised trial Lancet 2016 ; 387 : 357-66.
PubMed
5) Kelbaek H, et al. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER) : an open-label, randomised controlled trial. Lancet 2016 ; 387 : 2199-206.
PubMed
P.152 掲載の参考文献
1) Keeley EC, et al. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomized trials. Lancet 2003 ; 361 : 13-20.
PubMed
2) Nallamothu BK, et al. Time to treatment in primary percutaneous coronary intervention. N Engl J Med 2007 ; 357 : 1631-8.
PubMed
3) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告) : ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf
 
4) Bradley EH, et al. Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med 2006 ; 355 : 2308-20.
PubMed
5) Krumholz HM, et al. Improvements in door-to-balloon time in the United States, 2005 to 2010. Circulation 2011 ; 124 : 1038-45.
PubMed
6) Menees DS, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med 2013 ; 369 : 901-9.
PubMed
7) Shiomi H, et al. CREDO-Kyoto AMI investigators. Association of onset to balloon and door to balloon time with long term clinical outcome in patients with ST elevation acute myocardial infarction having primary percutaneous coronary intervention : observational study. BMJ 2012 ; 344 : e3257.
PubMed
8) 日本蘇生協議会, 日本救急医療財団監修. JRC蘇生ガイドライン 2010. 東京 : へるす出版 ; 2011.
 
9) Nakatsuma K, et al. Inter-Facility Transfer vs. Direct Admission of Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circ J 2016 ; 80 : 1764-72.
PubMed
P.158 掲載の参考文献
1) Ibanez BJ, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018 ; 39 : 119-77.
 
2) Stone GW, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011 ; 364 : 226-35.
PubMed
3) Smits PC, et al. Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. N Engl J Med 2017 ; 376 : 1234-44.
PubMed
4) Kornowski R, et al. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction : analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2011 ; 58 : 704-11.
 
5) Vlaar PJ, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction : a pairwise and network meta-analysis. J Am Coll Cardiol 2011 ; 58 : 692-703.
PubMed
6) Engstrom T, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI) : an open-label, randomised controlled trial. Lancet 2015 ; 386 : 665-71.
PubMed
7) Gershlick AH, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease : the CvLPRIT trial. J Am Coll Cardiol 2015 ; 65 : 963-72.
 
8) McCann GP, et al. Complete Versus Lesion-Only Primary PCI : The Randomized Cardiovascular MR CvLPRIT Substudy. J Am Coll Cardiol 2015 ; 66 : 2713-24.
PubMed
9) Hanratty CG, et al, Exaggeration of nonculprit stenosis severity during acute myocardial infarction : implications for immediate multivessel revascularization. J Am Coll Cardiol 2002 ; 40 : 911-6.
PubMed
10) Toyota T, et al. Culprit Vessel-Only vs. Staged Multivessel Percutaneous Coronary Intervention Strategies in Patients With Multivessel Coronary Artery Disease Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Circ J 2016 ; 80 : 371-8.
PubMed
11) Park JS, et al. Culprit or multivessel revascularisation in ST-elevation myocardial infarction with cardiogenic shock. Heart 2015 ; 101 : 1225-32.
 
12) Thiele H, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med 2017 ; 377 : 2419-32.
PubMed
13) Ahmed K, et al. Percutaneous coronary intervention with drug-eluting stent implantation vs. coronary artery bypass grafting for multivessel coronary artery disease in metabolic syndrome patients with acute myocardial infarction. Circ J 2012 ; 76 : 721-8.
PubMed
14) Marui A, et al. Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions </=50% versus > 50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Caldiol 2014 ; 114 : 988-96.
 
15) Davierwala PM, et al. Temporal Trends in Predictors of Early and Late Mortality After Emergency Coronary Artery Bypass Grafting for Cardiogenic Shock Complicating Acute Myocardial Infarction. Circulation 2016 ; 134 : 1224-37.
PubMed
16) Stone GW, et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med 2016 ; 375 : 2223-35.
 
P.170 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告) : 非ST上昇型急性冠症候群の診療に関するガイドライン (2012年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2012_kimura_h.pdf
 
2) Amsterdam EA, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 ; 130 : 2354-94.
 
3) Antman EM, et al. The TIMI risk score for umstable angina/non-ST elevation MI : A method for prognostication and therapeutic decision making. JAMA 2000 ; 284 : 835-42.
 
4) Granger CB, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003 ; 163 : 2345-53.
PubMed
5) Deharo P, et al. Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively : Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban). Circulation 2017 ; 136 : 1895-907.
PubMed
6) Aleksandra M, et al. Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients. The RIDDLE-NSTEMI Study. JACC Cardiovasc Interv 2016 ; 9 : 541-9.
 
7) Montalescot G, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013 ; 369 : 999-1010.
PubMed
8) Saito S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome : the PRASFIT-ACS study. Circ J 2014 ; 78 : 1684-92.
PubMed
9) de Zwaan C, et al. Characteristic electrocardiographic pattern indicating a critical stenosis high in left anterior descending coronary artery in patients admitted because of impending myocardial infarction. Am Heart J 1982 ; 103 : 730-6.
PubMed
10) de Zwaan C, et al. Angiographic and clinical characteristics of patients with unstable angina showing an ECG pattern indicating critical narrowing of the proximal LAD coronary artery. Am Heart J 1989 ; 117 : 657-65.
PubMed
P.175 掲載の参考文献
1) Levine GN, et al. Expert consensus document : World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014 ; 11 : 597-606.
PubMed
2) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告) : ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf
 
3) Rollini F, et al. Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention : The CRUSH Study. JACC 2016 ; 67 : 1994-2004.
PubMed
P.186 掲載の参考文献
1) Gibbons RJ, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999 ; 33 : 2092-197.
 
2) Pitt B, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000 ; 102 : 1503-10.
PubMed
3) Nissen SE, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure : the CAMELOT study : a randomized controlled trial. JAMA 2004 ; 292 : 2217-25.
PubMed
4) Lubsen J, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension : the ACTION trial. J Hypertens 2005 ; 23 : 641-8.
 
5) Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 2004 ; 93 : 969-73.
PubMed
6) Yui Y, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease : the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004 ; 27 : 181-91.
PubMed
7) Nishigaki K, et al. Prognostic effects of calcium channel blockers in patients with vasospastic angina-a meta-analysis. Circ J 2010 ; 74 : 1943-50.
PubMed
8) Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial. Lancet 2001 ; 357 : 1385-90.
PubMed
9) IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina : the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002 ; 359 : 1269-75.
 
10) Matsubara T, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol 2000 ; 35 : 345-51.
 
11) Yasue H, et al. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol 1999 ; 83 : 1308-13.
PubMed
12) Ogawa H, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes : a randomized controlled trial. JAMA 2008 ; 300 : 2134-41.
PubMed
13) Pfeffer MA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992 ; 327 : 669-77.
 
14) Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 ; 342 : 145-53.
PubMed
15) Fox KM, et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease : randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003 : 362 : 782-8.
PubMed
16) Dickstein K, et al. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction : the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002 ; 360 : 752-60.
PubMed
17) Pitt B, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure : randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000 ; 355 : 1582-7.
PubMed
18) ONTARGET Investigators. Yusuf S, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 ; 358 : 1547-59.
 
19) Sakamoto T, et al. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction : subanalysis of MUSASHI-AMI. Circ J 2007 ; 71 : 1348-53.
PubMed
20) Yokoyama M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet 2007 ; 369 : 1090-8.
PubMed
21) Matsuzaki M, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 2009 ; 73 : 1283-90.
PubMed
22) 日本動脈硬化学会編. 動脈硬化性疾患予防ガイドライン 2017年版. 日本動脈硬化学会 ; 2017.
 
P.194 掲載の参考文献
1) Head SJ, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease : final five-year follow-up of the SYNTAX trial. Eur Heart J 2014 ; 35 : 2821-30.
PubMed
2) Escaned J, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease : 1-year results of the SYNTAX II study. Eur Heart J 2017 ; 38 : 3124-34.
PubMed
3) Kobayashi Y, et al. The Prognostic Value of Residual Coronary Stenoses After Functionally Complete Revascularization. J Am Coll Cardiol 2016 ; 67 : 1701-11.
PubMed
4) Farooq V, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients : development and validation of SYNTAX score II. Lancet 2013 ; 381 : 639-50.
PubMed
5) Stone GW, et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med 2016 ; 375 : 2223-35.
 
P.202 掲載の参考文献
1) 梅原伸大ほか. JapanSCOREの有用性の検討-Logistic EuroSCOREとの比較を含めて. 日心外会誌 2013 ; 42 : 94-102,
 
2) Puskas JD, et al. Off-pump coronary artery bypass disproportionately benefits high-risk patients. Ann Thorac Surg 2009 ; 88 : 1142-7.
PubMed
3) Itatani K. Advance in Hemodynamic Research. New York : Nova Science ; 2015.
 
4) Numata S, et al. Blood flow analysis of the aortic arch using computational fluid dynamics. Eur J Cardiothorac Surg 2016 ; 49 : 1578-85,
PubMed
P.206 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告) : 冠攣縮性狭心症の診断と治療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawah_h.pdf
 
2) Ogawa T, et al. High incidence of repeat anginal attacks despite treatment with calcium-channel blockers in patients with coronary spastic angina. Circ J 2009 ; 73 : 512-5.
PubMed
3) Yasue H, et al. SCAST (Statin and Coronary Artery Spasm Trial) Investigators. Effect of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 2008 ; 51 : 1742-8.
PubMed
P.212 掲載の参考文献
1) Zellweger MJ, et al. Predictors and prognostic impact of silent coronary artery disease in asymptomatic high-risk patients with diabetes mellitus. Int J Cardiol 2017 ; 244 : 37-42.
PubMed
2) Beckrnan JA, et al. Diabetes and atherosclerosis : epidemiology, pathophysiology, and management. JAMA 2002 ; 287 : 2570-81.
 
3) Armstrong EJ, et al. Coronary artery revascularization in patients with diabetes mellitus. Circulation 2013 ; 128 : 1675-85.
PubMed
4) Pfisterer ME, et al. Management of stable coronary artery disease. Lancet 2010 ; 375 : 763-72.
PubMed
5) Gosselin G, et al. Effectiveness of percutaneous coronary intervention in patients with silent myocardial ischemia (post hoc anaiysis of the COURAGE trial). Am J Cardiol 2012 ; 109 : 954-9.
 
6) Yasue H, Kugiyama K. Coronary spasm : clinical features and pathogenesis. Intern Med 1997 ; 36 : 760-5.
PubMed
7) Davies RF, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up : outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997 ; 95 : 2037-43.
PubMed
8) Erne P, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction : the SWISSI II randomized controlled trial. JAMA 2007 ; 297 : 1985-91.
PubMed
P.220 掲載の参考文献
1) Raftery EB, et al. Occlusive disease of the coronary arteries presenting as primary congestive cardiomyopathy. Lancet 1969 ; 2 : 1146-50.
PubMed
2) Burch GE, et al. Ischemic cardiomyopathy. Am Heart J 1970 ; 79 : 291-2.
PubMed
3) Richardson P, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996 ; 93 : 841-2.
PubMed
4) Velazquez EJ, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med 2016 ; 374 : 1511-20.
PubMed
5) Felker GM, et al. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002 ; 39 : 210-8.
PubMed
6) McMurray JJ, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012 ; 33 : 1787-847.
 
7) Group CTS. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987 ; 316 : 1429-35.
 
8) Investigators S, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991 ; 325 : 293-302.
 
9) Granger CB, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors : the CHARM-Alternative trial. Lancet 2003 ; 362 : 772-6.
PubMed
10) Pfeffer MA, et at. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 ; 349 : 1893-906.
 
11) Waagstein F, et al, Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975 ; 37 : 1022-36.
PubMed
12) Swedberg K, et al. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979 ; 1 : 1374-6,
PubMed
13) Waagstein F, et al. Long-term beta-blockade in dilated cardiomyopathy. Effects of shortand long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989 ; 80 : 551-63.
 
14) Packer M, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med 1996 ; 334 : 1349-55.
 
15) Packer M, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 ; 344 : 1651-8.
PubMed
16) Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 ; 341 : 709-17.
 
17) Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 ; 348 : 1309-21.
PubMed
18) McMurray JJ, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014 ; 371 : 993-1004.
PubMed
19) Tsutsui H, et al. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction : Rationale for and design of the randomized, double-blind PARALLEL-HF study. J Cardiol 2017 ; 70 : 225-31.
PubMed
20) Epstein AE, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormallties : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) : developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008 ; 117 : e350-408.
 
21) McLeod CJ, et al. Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy. Heart Rhythm 2011 ; 8 : 377-82.
PubMed
22) Velazquez EJ, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011 ; 364 : 1607-16.
PubMed
23) Pagley PR, et al. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 1997 ; 96 : 793-800.
PubMed
24) Lee KS, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994 ; 90 : 2687-94.
PubMed
25) Baer FM, et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 1998 ; 31 : 1040-8.
PubMed
26) Allman KC, et al, Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction : a meta-analysis. J Am Coll Cardiol 2002 ; 39 : 1151-8.
PubMed
27) Bangalore S, et al. Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction : Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. Circulation 2016 ; 133 : 2132-40.
PubMed
28) Levine RA, et al. Mechanistic insights into functional mitral regurgitation. Curr Cardiol Rep 2002 ; 4 : 125-9.
PubMed
29) Smith PK, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2014 ; 371 : 2178-88.
PubMed
30) Michler RE, et al. Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation. N Engl J Med 2016 ; 374 : 1932-41.
PubMed
31) Chan KM, et al. Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation : final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation 2012 ; 126 : 2502-10.
 
32) Jones RH, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009 ; 360 : 1705-17.
 
P.236 掲載の参考文献
1) Fihn SD, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery. Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2014 ; 130 : 1749-67,
 
2) Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization : the Task Force on Myocardia [Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2014 ; 46 : 517-92.
 
3) Mohr FW, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease : 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013 ; 381 : 629-38.
PubMed
4) Puskas JD, et al. Off-pump coronary artery bypass disproportionately benefits high-risk patients. Ann Thorac Surg 2009 ; 88 : 1142-7.
PubMed

第4章 Expert Advice - 特殊な症例を管理する

P.240 掲載の参考文献
1) Thiele H, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med 2017 ; 377 : 2419-32.
PubMed
2) Thiele H, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012 ; 367 : 1287-96.
PubMed
3) O'Gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013 ; 61 : e78-140.
 
4) Windecker S, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization : The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014 ; 35 : 2541-619.
 
5) Mazzeffi M, et al. Bleeding, Transfusion, and Mortality on Extracorporeal Life Support : ECLS Working Group on Thrombosis and Hemostasis. Ann Thorac Surg 2016 ; 101 : 682-9,
 
6) O'Neill WW, et al. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock : results from the USpella Registry. J Interv Cardiol 2014 ; 27 : 1-11.
PubMed
7) Ouweneel DM, et al. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol 2017 ; 69 : 278-87.
PubMed
8) O'Neill WW, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention : the PROTECT II study. Circulation 2012 ; 126 : 1717-27.
PubMed
P.244 掲載の参考文献
1) International Diabetes Federation. IDF Diabetes Atlas. 7th edition 2015.
 
2) Caspard H, et al. Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA : An analysis of the NHANES surveys from 1999 to 2014. Diabetes Obes Metab 2018 ; 20 : 667-71.
PubMed
3) Rawshani A, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med 2017 ; 376 : 1407-18.
PubMed
4) Ryden L, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD : the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013 ; 34 : 3035-87.
 
5) Sattar N, et al. Novel Diabetes Drugs and the Cardiovascular Specialist. J Am Coll Cardiol 2017 ; 69 : 2646-56.
PubMed
6) Smits PC, et al. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus-and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice : The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice). JACC Cardiovasc Interv 2015 ; 8 : 1157-65.
 
7) Farkouh ME, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012 ; 367 : 2375-84.
PubMed
8) Ahn JM, et al. Comparison of Stenting Versus Bypass Surgery According to the Completeness of Revascularization in Severe Coronary Artery Disease : Patient-Level Pooled Analysis of the SYNTAX, PRECOMBAT, and BEST Trials. JACC Cardiovasc Interv 2017 ; 10 : 1415-24.
 
9) Salisbury A, et al. Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Diabetes : Insights From the OPEN CTO Registry. JACC Cardiovasc Interv 2017 ; 10 : 2174-81.
PubMed
10) Sanguineti F, et al. Chronic total coronary occlusion treated by percutaneous coronary intervention : long-term outcome in patients with and without diabetes. EuroIntervention 2017 ; 12 : e1889-97.
PubMed
P.248 掲載の参考文献
1) Anavekar NS, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004 ; 351 : 1285-95.
PubMed
2) Miyagi M, et al. Impact of renal function on coronary plaque composition. Nephrol Dial Transplant 2010 ; 25 : 175-81.
PubMed
3) Lee JM, et al. Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era : Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry. JACC Cardiovasc Interv 2016 ; 9 : 2097-109.
PubMed
4) Kono K et al. Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease. Kidney Int 2012 ; 82 : 344-51.
PubMed
5) Tsai TT, et al. Contemporary incidence. predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions : insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv 2014 ; 7 : 1-9.
PubMed
P.252 掲載の参考文献
1) 内閣府. 平成29年版高齢社会白書. http://www8.cao.go.jp/kourei/whitepaper/w-2017/zenbun/29pdf_index.html
 
2) Graham MM. Survival after coronary revascularization in the elderly. Circulation 2002 ; 105 : 2378-84.
PubMed
3) Tegn N, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study) : an open-label randomised controlled trial. Lancet 2016 ; 387 : 1057-65.
 
4) Alonso Salinas GL, et al. Frailty is a short-term prognostic marker in acute coronary syndrome of elderly patients. Eur Heart J Acute Cardiovasc Care 2016 ; 5 : 434-40.
 
5) Matsuzawa Y, et al. Association between gait speed as a measure of frailty and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2013 ; 61 : 1964-72.
PubMed
P.256 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2008-2009年度合同研究班報告) : 循環器領域における性差医療に関するガイドライン. http://www.j-circ.or.jp/guideline/pdf/JCS2010tei.h.pdf
 
2) Daly C, et al. Gender differences in the management and clinical outcome of stable angina. Circulation 2006 ; 113 : 490-8.
PubMed
3) Strehlow K, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003 ; 107 : 3059-65.
PubMed
4) Akishita M, et al, Estrogen inhibits cuff-induced intimal thickening of rat femoral artery : effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis 1997 ; 130 : 1-10,
PubMed
5) Cui Y, et al. Age-Specific Trends in the Incidence and In-Hospital Mortality of Acute Myocardial Infarction Over 30 Years in Japan-Report From the Miyagi AMI Registry Study. Circ J 2017 ; 81 : 520-8.
PubMed
6) Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes. Circulation 2008 ; 118 : 397-409.
PubMed
P.261 掲載の参考文献
1) Inoue H, et al. Prevalence of atrial fibrillation in the general population of Japan : an analysis based on periodic health exalnination. Int J Cardiol 2009 ; 137 : 102-7.
PubMed
2) Toyoda K, et al. Dual antithrombotic therapy increas es severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke 2008 ; 39 : 1740-5.
 
3) Uchida Y, et al. Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents. J Cardiol 2010 ; 55 : 362-9.
 
4) Dewilde WJ, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing Percutaneous coronary intervention : an open-label. randomised, controlled trial Lancet 2013 ; 381 : 1107-15.
 
5) Lip GY, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing Percutaneous coronary or valve interventions : a joint consensus document of the European Society of Cardiology Working Group on Thrombosist European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014 ; 35 : 3155-79.
 
6) Lamberts M, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant : a nationwide cohort study. Circulation 2014 ; 129 : 1577-85.
PubMed
7) Valgimigli M, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS : The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018 ; 39 : 213-60.
 
8) Gibson CM, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 ; 375 : 2423-34.
PubMed
9) Shen AY, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007 ; 50 : 309-15.
PubMed
10) Amouyel P, et al. INR variability in atrial fibrillation : a risk model for cerebrovascular events. Eur J Intern Med 2009 ; 20 : 63-9.
PubMed
11) Yamashita T, et al. Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients : a J-RHYTHM Registry analysis. J Cardiol 2015 ; 65 : 175-7.
 
12) Cannon CP, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017 ; 377 : 1513-24.
PubMed
13) Yasuda S, et al. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE) : Protocol for a multicenter, prospective, randomized, open-label, parallel group study. Int J Cardiol 2018 ; pii : S0167-5273 (17) 36755-4.
 
P.264 掲載の参考文献
1) American Association for Thoracic Surgery Ischemic Mitral Regurgitation Consensus Guidelines Writing Committee, Kron IL, et al. 2015 The American Association for Thoracic Surgery Consensus Guidelines : Ischemic mitral valve regurgitation. J Thorac Cardiovasc Surg 2016 ; 151 : 940-56.
 
2) Nishimura RA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017 ; 70 : 252-89.
 
3) Michler RE, et al ; CTSN. Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation. N Engl J Med 2016 ; 374 : 1932-41.
PubMed
4) Goldstein D, et al ; CTSN. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med 2016 ; 374 : 344-53.
PubMed
5) Nappi F, et al. Papillary Muscle Approximation Versus Restrictive Annuloplasty Alone for Severe Ischemic Mitral Regurgitation. J Am Coll Cardiol 2016 ; 67 : 2334-46.
PubMed
6) Komeda M, et al. "Papillary heads optimization" for more geometric repair of functional mitral regurgitation toward ventricular treatment. Ann Cardiothorac Surg 2015 ; 4 : 393-6.
PubMed
P.266 掲載の参考文献
1) Thourani VH, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients : a propensity score analysis. Lancet 2016 ; 387 : 2218-25.
PubMed
2) Nishimura RA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017 ; 135 : e1159-95.
 
3) Baumgartner H, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017 ; 38 : 2739-91.
PubMed
4) Goel SS, et al. Severe aortic stenosis and coronary artery disease--implications for management in the transcatheter aortic valve replacement era : a comprehensive review. J Am Coll Cardiol 2013 ; 62 : 1-10.
 
5) Bajaj A, et al. Safety and feasibility of PCI in patients undergoing TAVR : A systematic review and meta-analysis. Heart Lung 2017 ; 46 : 92-9.
PubMed
6) Stefanini GG, et al. Coronary artery disease severity and aortic stenosis : clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. Eur Heart J 2014 ; 35 : 2530-40.
PubMed
7) Otto CM, et al. 2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis : A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2017 ; 69 : 1313-46.
 
8) Goel SS, et al. Percutaneous coronary intervention in patients with severe aortic stenosis : implications for transcatheter aortic valve replacement. Circulation 2012 ; 125 : 1005-13.
PubMed
9) Naganuma T, et al. Can we perform rotational atherectomy in patients with severe aortic stenosis? Substudy from the OCEAN TAVI Registry. Cardiovasc Revasc Med 2017 ; 18 : 356-60.
PubMed
P.269 掲載の参考文献
1) Shiba N, et al ; CHART-2 Investigators. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-first report from the CHART-2 study. Circ J 2011 ; 75 : 823-33.
PubMed
2) prognosis ; CHART-2 Investigators. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan-report from the CHART Studies. Circ J 2015 ; 79 : 2396-407.
PubMed
3) Hochman JS, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators, Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999 ; 341 : 625-34.
PubMed
4) Sato N, et al : ATTEND Investigators. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 2013 ; 77 : 944-51.
PubMed
5) Velazquez EJ, et al ; STICH Investigators, Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011 ; 364 : 1607-28.
PubMed
6) Velazquez EJ, et al : STICHES Investigators. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. . N Engl J Med 2016 ; 374 : 1511-20.
PubMed
7) Bonow RO, et al : STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011 ; 364 : 1617-25.
PubMed
8) Marui A, et al ; CREDO-Kyoto CABG Registry Cohort-2 Investigators. Three-year outcomes after percutaneous coronary intervention and coronary artery bypass grafting in patients with heart failure : from the CREDO-Kyoto percutaneous coronary intervention/coronary artery bypass graft registry cohort-2. Eur J Cardiothorac Surg 2015 ; 47 : 316-21.
PubMed
P.273 掲載の参考文献
1) Fleisher LA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery : Executive Summary : A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) : Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007 ; 116 : 1971-96.
 
2) Lee TH, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999 ; 100 : 1043-9.
PubMed
3) 日本循環器学会. 2012-2013年度合同研究班報告 : 非心臓手術における合併心疾患の評価と管理に関するガイドライン (2014年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2014_kyo_h.pdf
 
4) Kristensen SD, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery : cardiovascular assessment and management : The Joint Task Force on non-cardiac surgery : cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA), Eur Heart J 2014 ; 35 : 2383-431.
 
5) Fleisher LA, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 ; 130 : 2215-45.
 
6) Valgimigli M, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS : The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018 ; 39 : 213-60.
 
7) Wijeysundera DN, et al. Perioperative beta blockade in noncardiac surgery : asystematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2014 ; 64 : 2406-25.
 
P.279 掲載の参考文献
1) Suda K, et al. Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysm : a single institution experience. Circulation 2011 ; 123 : 1836-42.
PubMed
2) Tsuda E, et al. The 30-year outcome of patients after myocardial infarction due to coronary lesions caused by Kawasaki disease. Pediatr Cardiol 2011 ; 32 : 176-82.
PubMed
3) Danieis LB, et al. Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia. Circulation 2012 ; 125 : 2447-53.
 
4) Inaba S, et al. Successful revascularization by pulse infusion thrombolysis in a patients with Kawasaki disease combined with acute myocardial infarction. JACC Cardiovasc Interv 2010 ; 3 : 1091-2.
 
5) Ariyoshi M, et al, Primary percutaneous coronary intervention for acute myocardial infarction due to possible sequelae of Kawasaki disease in young adults a case series. Heart Vessels 2011 ; 26 : 117-24.
PubMed
6) Peters TF, et al. Rotational ablation and stent placement for severe calcific coronary artery stenosis after Kawasaki disease. Catheter Cardiovasc Interv 2002 ; 56 : 549-52.
PubMed
7) Akagi T. Interventions in Kawasaki disease, Pediatr Cardiol 2005 ; 26 : 206-12.
PubMed
8) Yokouchi Y, et al. Repeated sent thrombosis after DES implantation and localized hypersensitivity to a stent implanted in the distal portion of a coronary aneurysm thought to be a sequela of Kawasaki disease : autopsy report. Pathol Int 2010 ; 60 : 112-8.
 

第5章 虚血を防ぐ - 虚血性心疾患の二次予防

P.288 掲載の参考文献
1) Boden WE, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007 ; 356 : 1503-16.
 
2) Dzau VJ, et al. The cardiovascular disease continuum validated : clinical evidence of improved patient outcomes : part I : Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006 ; 114 : 2850-70.
PubMed
3) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告) : 心筋梗塞二次予防に関するガイドライン (2011年改訂版, 2013年更新版). http://www.j-circ.or.jp/guideline/pdf/JCS2011_ogawah_h.pdf
 
4) Smith SC Jr, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease : 2011 update : a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011 : 124 : 2458-73.
 
5) Goyal A, et al. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg 2007 : 83 : 993-1001.
PubMed
6) Iqbal J, et al. Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting : insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up. Circulation 2015 ; 131 : 1269-77.
PubMed
7) Kumbhani DJ, et al. Adherence to secondary prevention medications and four-year out-comes in outpatients with atherosclerosis. Am J Med 2013 ; 126 : 693-700.
 
8) Turnbull F, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007 ; 25 : 951-8.
PubMed
P.293 掲載の参考文献
1) Levine GN, et al. Expert consensus document : World heart federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014 ; 11 : 597-606.
PubMed
2) Kim IS, et al. The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. J Thromb Haemost 2009 ; 7 : 897-9.
PubMed
3) Yeh RW, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 2016 ; 315 : 1735-49.
PubMed
4) Baber U, et al. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents : Risk Scores From PARIS. J Am Coll Cardiol 2016 ; 67 : 2224-34.
 
5) Costa F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score : a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017 ; 389 : 1025-34,
 
6) Mak KH, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in theClopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J 2009 ; 157 : 658-65.
PubMed
7) Shen AY, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007 ; 50 : 309-15.
PubMed
P.299 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会編. 高血圧治療ガイドライン 2014, ライフサイエンス出版 : 2014.
 
2) Rosendorff C, et al. Treatment of hypertension in patients with coronary artery disease : A scientific statement from the American Heart Association. American College of Cardiology, and American Society of Hypertension. Hypertension 2015 ; 65 : 1372-407.
 
3) Pepine CJ, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST) : A randomized controlled trial. JAMA 2003 ; 290 : 2805-16.
 
4) Hasebe N, et al. Reverse J-curve relation between diastolic blood pressure and severity of coronary artery lesion in hypertensive patients with angina pectoris. Hypertens Res 2002 ; 25 : 381-7.
 
5) SPRINT Research Group, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015 ; 373 : 2103-16.
 
6) Toyoda K, et al. Blood pressure levels and bleeding events during antithrombotic therapy : The Bleeding with Antithrombotic Therapy (BAT) Study. Stroke 2010 ; 41 : 1440-4.
PubMed
7) Andersson C, et al. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol 2014 ; 64 : 247-52.
 
P.305 掲載の参考文献
1) Nordestgaard BG, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population : guidance for clinicians to prevent coronary heart disease : consensus statement of the European Atherosclerosis Society. Eur Heart J 2013 ; 34 : 3478-90a.
PubMed
2) Ference BA, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both : a 2×2 factorial Mendelian randomization study. J Am Coll Cardiol 2015 ; 65 : 1552-61,
 
3) Kawashiri M, et al. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. Am J Cardiol 2012 ; 109 : 364-9.
PubMed
4) Giugliano RP, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab : a prespecified secondary analysis of the FOURIER trial. Lancet 2017 ; 390 : 1962-71.
PubMed
5) Kawashiri MA, et al. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Atherosclerosis 2017 ; 265 : 225-30.
PubMed
P.313 掲載の参考文献
1) Dormandy JA, et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomized controlled trial. Lancet 2005 ; 366 : 1279-89.
PubMed
2) Kernan WN, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med 2016 ; 374 : 1321-31.
 
3) Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015 ; 373 : 2117-28.
PubMed
4) Neal B, et al, Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017 ; 377 : 644-57.
PubMed
5) Mahaffey KW, et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events : Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018 ; 137 : 323-34.
PubMed
6) Marso SP, et al ; LEADER Steering Committee ; LEADER Trial Investigators, Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016 ; 375 : 311-22.
 
7) Marso SP, et al ; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016 ; 375 : 1834-44.
PubMed
8) Margulies KB, et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction : A Randomized Clinical Trial. JAMA 2016 ; 316 : 500-8.
PubMed
9) Roussel R, et al. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes : A perspective on glucose-lowering interventions. Diabetes Obes Metab 2018 ; 20 : 238-44.
PubMed
10) Ueki K, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3) : an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017 ; 5 : 951-64.
PubMed
P.318 掲載の参考文献
1) Bhatt AS, et al. Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. Curr Cardiol Rep 2017 ; 19 : 71.
 
2) Funaro S. et al, Incidence, determinants. and prognostic value of reverse left ventricular remodeling after primary percutaneous coronary intervention : results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J 2009 ; 30 : 566-75.
PubMed
3) Heydari B, et al. Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction : The OMEGA-REMODEL Randomized Clinical Triai. Circulation 2016 ; 134 : 378-91.
 
4) Haykowsky M, et al. A meta-analysis of the effects of exercise training on left ventricular remodeling following myocardial infarction : start early and go longer for greatest exercise benefits on remodeling. Trials 2011 ; 12 : 92.
 
P.324 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告) : 心血管疾患におけるリハビリテーションに関するガイドライン (2012年改訂版). p8-12. http://www.j-circ.or.jp/guideline/pdf/JCS2012_nohara_h.pdf
 
2) Taylor RS, et al. Exercise-based rehabilitation for patients with coronary heart disease : systematic review and meta-analysis of randomized controlled trials. Am J Med 2004 ; 116 : 682-92.
PubMed
3) Witt BJ, et al. Cardiac rehabilitation after myocardial infarction in the community. J Am Coll Cardiol 2004 ; 44 : 988-96.
PubMed
4) Goel K, et al. Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation 2011 ; 123 ; 2344-52.
PubMed
5) Pack QR, et al. Participation in cardiac rehabilitation and survival after coronary artery bypass graft surgery : a community-based study. Circulation 2013 ; 128 : 590-7.
PubMed
6) Ornish D, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990 ; 336 : 129-33.
PubMed
7) Schuler G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992 ; 86 : 1-11.
PubMed
8) Sdringola S, et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol 2003 ; 41 : 263-72.
PubMed
9) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告) : 心筋梗塞二次予防に関するガイドライン (2011年改訂版), p. 15-7. http://www.j-circ.or.jp/guideline/pdf/JCS2011_ogawah_h.pdf
 

第6章 Current Topics - 診断と治療の最新動向

P.329 掲載の参考文献
1) Wykrzykowska JJ, et al. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. N Engl J Med 2017 ; 376 : 2319-28.
PubMed
2) Toyota T, et al. Very Late Scaffold Thrombosis of Bioresorbable Vascular Scaffold : Systematic Review and a Meta-Analysis. JACC Cardiovasc Interv 2017 ; 10 : 27-37.
 
3) Collet C, et al. Late thrombotic events after bioresorbable scaffold implantation : a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2017 ; 38 : 2559-66.
PubMed
4) Onuma Y, et al. Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold : the ABSORB cohort B MSCT substudy. Eur Heart J Cardiovasc Imaging 2017 ; 18 : 870-9.
PubMed
5) Schnorbus B, et al. Twelve-month outcomes after Bioresorbable Vascular Scaffold implantation in Patients with Acute Coronary Syndromes. Data from the European Multicentre GHOST-EU Extended Registry. EuroIntervention 2017 ; 13 : e1104-11.
 
6) Karanasos A, et al. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis : single-center experience. Circ Cardiovasc Interv 2015 ; 8. pii : e002369.
 
P.333 掲載の参考文献
1) Norgaard BL, et al. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease : the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography : Next Steps). J Am Coll Cardiol 2014 ; 63 : 1145-55.
 
2) Douglas PS, et al. Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease : the prospective longitudinal trial of FFR (CT) : outcome and resource impacts study. Eur Heart J 2015 ; 36 : 3359-67.
PubMed
3) Curzen NP, et al. Does the Routine Availability of CT-Derived FFR Influence Management of Patients With Stable Chest Pain Compared to CT Angiography Alone? : The FFRCT RIPCORD Study. JACC Cardiovasc Imaging 2016 ; 9 : 1188-94.
 
4) Kimura T, et al. Cost analysis of non-invasive fractional flow reserve derived from coronary computed tomographic angiography in Japan. Cardiovasc Interv Ther 2015 ; 30 : 38-44.
PubMed
5) Tu S, et al. Fractional flow reserve calculation from 3-dimensional quantitative coronary angiography and TIMI frame count : a fast computer model to quantify the functional significance of moderately obstructed coronary arteries. JACC Cardiovasc Interv 2014 ; 7 : 768-77.
 
6) Tu S, et al. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography : The International Multicenter FAVOR Pilot Study. JACC Cardiovasc Interv 2016 ; 9 : 2024-35.
PubMed
P.337 掲載の参考文献
1) Patel MR, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/ SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. J Am Coll Cardiol 2017 ; 69 : 2212-41.
 
2) Patel MR, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate Use Criteria for Coronary Revascularization in Patients With Acute Coronary Syndromes : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2017 ; 69 : 570-91.
 
3) Sedlis SP, et al : COURAGE Trial Investigators. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. N Engl J Med 2015 ; 373 : 1937-46.
PubMed
4) Chan PS, et al. Appropriateness of percutaneous coronary intervention. JAMA 2011 ; 306 : 53-61.
PubMed
5) Desai NR, et al. Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. JAMA 2015 ; 314 : 2045-53.
PubMed
6) Inohara T, et al. Appropriateness ratings of percutaneous coronary intervention in Japan and its association with the trend of noninvasive testing. JACC Cardiovasc Interv 2014 ; 7 : 1000-9.
PubMed
7) Inohara T, et al. Application of appropriate use criteria for percutaneous coronary intervention in Japan. World J Cardiol 2016 ; 8 : 456-63.
PubMed
P.341 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告) : 安定冠動脈疾患における待機的PCIのガイドライン (2011年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2011_fujiwara_h.pdf
 
2) Task Force members, Windecker S, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization : The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014 ; 35 : 2541-619.
 
P.345 掲載の参考文献
1) 日本動脈硬化学会編. 動脈硬化性疾患予防ガイドライン 2017年版. 日本動脈硬化学会 : 2017.
 
2) Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 ; 376 : 1670-81.
PubMed
3) McKenney JM. Optimizing LDL-C lowering with statins. Am JT her 2004 ; 11 : 54-9.
 
4) Teramoto T, et al. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world : An analysis of more than 33,000 high cardiovascuiar risk patients in Japan. Atherosclerosis 2016 ; 251 : 248-54.
 
5) Ota T, et al. Impact of the statin escape phenomenon on long-term clinical outcomes in patients with acute myocardial infarction : Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS). Atherosclerosis 2015 ; 242 : 155-60.
PubMed
6) Mammem AL. Statin-Associated Autoimmune Myopathy. N Eng J Med 2016 ; 374 : 664-9.
 
7) Mann DM, et al. Predictors of nonadherence to statins : a systematic review and meta-analysis. Ann Pharmacother 2010 ; 44 : 1410-21.
PubMed
8) Shalev V, et al. Continuation of statin treatment and all-cause mortality : a population-based cohort study. Arch Intern Med 2009 ; 169 : 260-8.
PubMed
9) Nordestgaard BG, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population : guidance for clinicians to prevent coronary heart disease : consensus statement of the European Atherosclerosis Society. Eur Heart J 2013 : 34 : 3478-90a.
PubMed
10) Tada H, et al. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur Heart J 2017 ; 38 : 1573-9.
PubMed
11) Civeira F, et al. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. Arterioscler Thromb Vasc Biol 2005 ; 25 : 1960-5.
PubMed
P.348 掲載の参考文献
1) Levine GN, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016 ; 68 : 1082-115.
 
2) Nakamura M, et al. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation. JACC Cardiovasc Interv 2017 ; 10 : 1189-98.
PubMed
3) Mauri L, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014 ; 371 : 2155-66.
 
4) Palmerini T, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes : an individual patient data pairwise and network meta-analysis of six randomized trials and 11473 patients. Eur Heart J 2017 ; 38 : 1034-43.
 
5) Costa F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score : a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017 ; 389 : 1025-34.
 
P.353 掲載の参考文献
1) Lund LH, et al. The Registry of the International Society for Heart and Lung Transplantation : Thirty-fourth Adult Heart Transplantation Report-2017 ; Focus Theme : Allograft ischemic time. J Heart Lung Transplant 2017 ; 36 : 1037-46.
PubMed
2) Chih S, et al. Allograft Vasculopathy : The Achilles' Heel of Heart Transplantation. J Am Coll Cardiol 2016 ; 68 : 80-91.
PubMed
3) Spes CH, et al. Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy : a comparison with coronary angiography and intravascular ultrasound. Circulation 1999 ; 100 : 509-15.
PubMed
4) Murthy VL, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 2011 ; 124 : 2215-24.
PubMed
5) Miller CA, et al. Multiparametric cardiovascular magnetic resonance assessment of cardiac allograft vasculopathy. J Am Coll Cardiol 2014 ; 63 : 799-808.
PubMed
6) Wever-Pinzon O, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy : a meta-analysis of prospective trials. J Am Coll Cardiol 2014 ; 63 : 1992-2004.
PubMed
7) Costanzo MR, et al. Heart transplant coronary artery disease detected by coronary angiography : a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 1998 ; 17 : 744-53.
PubMed
8) Rickenbacher PR, et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 1995 ; 92 : 3445-52.
PubMed
9) Dong L, et al. Optical coherence tomographic evaluation of transplant coronary artery vasculopathy with correlation to cellular rejection. Circ Cardiovasc Interv 2014 ; 7 : 199-206.
PubMed
10) de Lorgeril M, et al. Increased platelet aggregation after heart transplantation : influence of aspirin. J Heart Lung Transplant 1991 ; 10 : 600-3.
PubMed
11) Mehra MR, Raval NY. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant Proc 2004 ; 36 : 1539-41.
PubMed
12) Schroeder JS, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993 ; 328 : 164-70.
PubMed
13) Eisen HJ, et al. RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003 ; 349 : 847-58.
 
14) Mancini D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003 ; 108 : 48-53.
PubMed
15) Arora S, et al. Effect of everolimus introduction on cardiac allograft vasculopathy-results of a randomized, multicenter trial. Transplantation 2011 ; 92 : 235-43.
PubMed
16) Lee MS, et al. Long-term outcomes of heart transplantation recipients with transplant coronary artery disease who develop in-stent restenosis after percutaneous coronary intervention. Am J Cardiol 2012 ; 109 : 1729-32.
PubMed
17) Ono M, Michler RE. Beating heart coronary artery bypass surgery after orthotopic heart transplantation. J Card Surg 2003 ; 18 : 545-9.
PubMed
P.357 掲載の参考文献
1) Ross AM, et al. Prevalence of spinal disc disease among interventional cardiologists. Am J Cardiol 1997 ; 79 : 68-70.
PubMed
2) Goldstein JA, et al. Occupational hazards of interventional cardiologists : prevalence of orthopedic health problems in contemporary practice. Catheter Cardiovasc Interv 2004 ; 63 : 407-11.
PubMed
3) Duran A, et al. Retrospective evaluation of lens injuries and dose : RELID study. JACC 2011 ; 57 ; issue14.
 
4) Cirac-Bejelac O, et al. Risk for radiation-induced cataract for staff in interventional cardiology : is there reason for concern? Catheter Cardiovasc Interv 2010 ; 76 : 826-34.
 
5) Rehani MM, et al. Radiation and cataract. Radiat Prot Dosimetry 2011 ; 147 : 300-4.
PubMed
6) Roguin A, et al. Brain tumours among interventional cardiologists : acause for alarm? Report of four new cases from two cities and review of literature. EuroIntrevention 2012 ; 7 : 1081-6.
 
7) Roguin A, et al. Brain malignancies and ionizing radiation : more cases reported. EuroIntervention 2012 ; 8 : 169-70.
PubMed
8) Miller DL, et al. New recommendations for occupational radiation protection. J Am Coll Radiol 2012 ; 9 : 366-8.
PubMed
9) Weisz G, et al, Safety and feaslbility of robotic percutaneous coronary intervention : PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study. J Am Coll Cardiol 2013 ; 61 : 1596-600.
PubMed
10) Bezerra HG, et al. Longitudinal Geographic Miss (LGM) in Robotic Assisted Versus Manual Percutaneous Coronary Interventions. J Interv Cardiol 2015 ; 28 : 449-55.
PubMed
11) Mahmud E, et al. Demonstration of the Safety and Feasibility of Robotically Assisted Percutaneous Coronary Intervention in Complex Coronary Lesions : Results of the CORA-PCI Study (Complex Robotically Assisted Percutaneous Coronary Intervention). JACC Cardiovasc Interv 2017 ; 10 : 1320-7.
PubMed
12) Kapur V, et al. Complex robotic-enhanced percutaneous coronary intervention. Catheter Cardiovasc Interv 2014 ; 83 : 915-21.
PubMed
P.362 掲載の参考文献
1) Task Force members, Windecker S, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization : The Task Force on Myocardial Revascularization of the Euro-pean Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014 ; 35 : 2541-619.
 
2) Miura K, et al. Stent Fracture and Peri-Stent Contrast Staining After Everolimus-Eluting Stent Implantation-5-Year Outcomes. Circ J 2017 ; 81 : 1514-21.
PubMed
3) Ohya M, et al. Incidence, predictive factors, and clinical impact of stent recoil in stent fracture lesion after drug-eluting stent implantation. Int J Cardiol 2016 ; 214 : 123-9.
PubMed
4) Tada T, et al. Association between tissue characteristics assessed with optical coherence tomography and midterm results after percutaneous coronary intervention for in-stent restenosis lesions : a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation. Eur Heart J Cardiovasc Imaging 2015 ; 16 : 1101-11.
PubMed
5) Habara S, et al. Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis. J Am Coll Cardiol 2015 ; 66 : 14-22.
PubMed
6) Miura K, et al. Five-Year Outcomes After Paclitaxel-Coated Balloon Angioplasty for Drug-Eluting Stent Restenosis. Am J Cardiol 2017 ; 119 : 365-71.
PubMed
7) Alfonso F, et al ; RIBS IV Study Investigators (under auspices of Interventional Cardiology Working Group of Spanish Society of Cardiology). A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents : The RIBS IV Randomized Clinical Trial. J Am Coll Cardiol 2015 ; 66 : 23-33.
 
8) Kubo S, et al. Everolimus-eluting stent implantation versus repeat paclitaxel-coated balloon angioplasty for recurrent in-stent restenosis lesion caused by paclitaxel-coated balloon failure. EuroIntervention 2015 ; 10 : e1-8.
PubMed
P.366 掲載の参考文献
1) Kubo T, Akasaka T. Gray-scale intravascular ultrasound sheds light on the importance of vasa vasorum in unstable coronary plaque. J Cardiol 2017 ; 69 : 599-600.
PubMed
2) Kubo T, Akasaka T. Angioscopy and Unstable Coronary Plaques : Findings Beyond Thrombus, Curr Cardiovasc Imgaging Rep 2011 ; 4 : 284-91.
 
3) Kubo T, et al. Plaque and thrombus evaluation by optical coherence tomography. Int J Cardiovasc Imaging, 2011 ; 27 : 289-98.
PubMed
4) Kubo T, et al. Assessment of coronary atherosclerosis using optical coherence tomography. J Atheroscler Thromb 2014 ; 21 : 895-903.
PubMed
5) Kubo T, et al. Suboptimal agreements between optical coherence tomography and near infrared spectroscopy for identification of lipid-laden plaque, EuroIntervention 2017 : 13 : 263-4.
PubMed

書評

最近チェックした商品履歴

Loading...